Demographic shifts, such as aging populations and changing lifestyles, contribute to the increasing demand for gynecological devices. As women age, they may experience menopausal symptoms, pelvic floor disorders, and other reproductive health issues, necessitating specialized devices and treatment options to address their unique healthcare needs.
Furthermore, regulatory initiatives aimed at improving healthcare quality and patient safety, coupled with reimbursement policies favoring minimally invasive procedures, drive the adoption of advanced gynecological devices. Manufacturers and healthcare providers are incentivized to invest in innovative technologies and devices that enhance clinical outcomes while minimizing patient discomfort and recovery time.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The gynecological devices market size was valued at USD 9.7 billion in 2023 and is estimated to grow at 8.1% CAGR from 2024 to 2032, driven by advancements in medical technology and digital imaging systems.
The hospitals and clinics segment of the market recorded USD 4.3 billion in 2023 and will expand rapidly through 2032, as patient preferences and expectations drive the demand for patient-centered care models in hospitals and clinics.
North America gynecological devices market is forecasted to reach USD 8.9 billion by 2032, propelled by rapidly aging population, and technological advancements.
Abbott Laboratories, Bayer AG, Boston Scientific Corporation, CooperSurgical, Inc, Fresenius Medical Care AG & Co. KGaA, Hologic, Inc, Intuitive Surgical, Inc, and Johnson & Johnson (Ethicon, Inc.) among others.